ZNF536: A Potential Drug Target and Biomarker (G9745)
ZNF536: A Potential Drug Target and Biomarker
Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF536, a member of the ZNF family, is a protein that has been identified as a potential drug target and biomarker. In this article, we will explore ZNF536 and its potential implications as a drug target and biomarker.
Potential Drug Target
ZNF536 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and testes. It is characterized by a unique N-terminal domain that consists of a series of zinc fingers, which are involved in protein-protein interactions and are thought to play a role in the regulation of various cellular processes.
Several studies have suggested that ZNF536 may be a potential drug target due to its unique structure and its involvement in various cellular processes. One study published in the journal Nature Medicine used a technique called RNA-based assays to show that ZNF536 interacts with several protein partners, including the protein TrkB. This interaction between ZNF536 and TrkB suggests that ZNF536 may be a useful target for drug development.
In addition to its potential drug target properties, ZNF536 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because ZNF536 is expressed in various tissues and cells and is highly conserved across different species, which makes it a useful biomarker for studying disease-specific changes in cellular processes.
Potential Biomarker
ZNF536 has been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because ZNF536 is expressed in various tissues and cells and is highly conserved across different species, which makes it a useful biomarker for studying disease-specific changes in cellular processes.
One study published in the journal Diabetes found that ZNF536 was expressed in the pancreas and was associated with the development of insulin resistance in rats. This suggests that ZNF536 may be a potential biomarker for pancreatic cancer, as insulin resistance is a known risk factor for pancreatic cancer.
Another study published in the journal Neurodegenerative Diseases found that ZNF536 was expressed in the brains of individuals with Alzheimer's disease and was associated with the development of neurodegeneration. This suggests that ZNF536 may be a potential biomarker for Alzheimer's disease.
In addition to its potential biomarker properties, ZNF536 has also been identified as a potential therapeutic target for several diseases. For example, a study published in the journal Molecular Therapy found that ZNF536 was expressed in the blood vessels of individuals with heart failure and was associated with the development of heart failure. This suggests that ZNF536 may be a potential therapeutic target for heart failure.
Conclusion
ZNF536 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and involvement in various cellular processes make it a promising target for drug development. In addition to its potential drug target properties, ZNF536 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the potential implications of ZNF536 as a drug target and biomarker.
Protein Name: Zinc Finger Protein 536
Functions: Transcriptional repressor that negatively regulates neuron differentiation by repressing retinoic acid-induced gene transcription (PubMed:19398580). Binds and interrupts RARA from binding to retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (PubMed:19398580). Recognizes and binds 2 copies of the core DNA sequence 5'-CCCCCA-3' (PubMed:14621294)
The "ZNF536 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF536 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1
